2-((5-Methyloxazol-2-yl)methyl)isoindoline-1,3-dione

Catalog No. :
ACSSOT475
CAS No. :
1133256-82-2
Molecular Formula :
C13H10N2O3
Molecular Weight :
242.23

IUPAC Name:2-((5-methyloxazol-2-yl)methyl)isoindoline-1,3-dione

2-((5-Methyloxazol-2-yl)methyl)isoindoline-1,3-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$195.00Login to see priceInquiryInquiry
250mg98%$312.00Login to see priceInquiryInquiry
1g98%$702.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-((5-Methyloxazol-2-yl)methyl)isoindoline-1,3-dione
IUPAC Name2-((5-methyloxazol-2-yl)methyl)isoindoline-1,3-dione
MDL No.MFCD28139403
Molecular FormulaC13H10N2O3
Molecular Weight242.23
SMILESO=C1N(CC2=NC=C(C)O2)C(C3=C1C=CC=C3)=O
InChI KeySIHCAINVXGPLDZ-UHFFFAOYSA-N
Synonym2-[(5-Methyl-1,3-oxazol-2-yl)methyl]-2,3-dihydro-1H-isoindole-1,3-dione;1H-Isoindole-1,3(2H)-dione, 2-[(5-methyl-2-oxazolyl)methyl]-
CAS No.1133256-82-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACSSOT475 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJDOI249 route compound structure diagram
    ACJDOI2491074-82-4 In Stock
  4. Then
  5. ACSSOT475 route product structure diagram
    ACSSOT4751133256-82-2
Inquiry

2. ACSSOT475 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJDOI249 route compound structure diagram
    ACJDOI2491074-82-4 In Stock
  4. Then
  5. ACSSOT475 route product structure diagram
    ACSSOT4751133256-82-2
Inquiry

Comments (0)